Sermorelin Compounding Pharmacy FDA and State Board Enforcement History

What Sermorelin Is and Why It Is Compounded

Sermorelin acetate is a synthetic analogue of the first 29 amino acids of endogenous growth-hormone-releasing hormone. The FDA approved a branded sermorelin injection (Geref) in 1997, but the manufacturer voluntarily withdrew it from the US market in 2008. Because no commercially manufactured sermorelin product is currently available, every sermorelin vial dispensed in the United States today is a compounded preparation. That single fact places it squarely inside a regulatory framework that has drawn escalating FDA scrutiny since 2015.

Why Compounding Fills the Gap

Compounders operating under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) may prepare sermorelin for individual patients when a licensed prescriber writes a patient-specific prescription. Larger outsourcing facilities registered under Section 503B may produce sermorelin in anticipation of orders without patient-specific prescriptions, provided they comply with Current Good Manufacturing Practice (CGMP) requirements. The FDA's guidance on compounding from bulk drug substances outlines which substances may be used and under what conditions. [1]

The Bulk Drug Substance Question

Sermorelin sits on a list of substances under active FDA evaluation for inclusion on the 503B Bulks List. The agency has stated it will take enforcement action against 503B facilities compounding substances not yet nominated or not yet evaluated. Prescribers and patients should verify that the dispensing facility has current legal authority to compound sermorelin before a prescription is filled. [2]

FDA Warning Letters and Enforcement Actions Against Compounders

The FDA has issued dozens of warning letters to sterile compounding pharmacies over the past decade. Several have directly cited peptide products, and the deficiencies found at those facilities apply directly to sermorelin manufacturing.

Documented Deficiency Categories

A 2023 FDA warning letter to a Florida sterile compounder identified six separate violations of USP <797>, including inadequate environmental monitoring, failure to perform media-fill validation, and use of bulk drug substances not on the approved list. [3] A 2021 warning letter to a Texas 503B facility cited sub-potent peptide content confirmed by HPLC assay, with active pharmaceutical ingredient levels ranging from 74% to 112% of labeled claim. [4]

The FDA's database of compounding warning letters shows that sterility failures are the most commonly cited deficiency across all sterile compounders, followed by inadequate beyond-use dating (BUD) and failure to conduct stability testing. [5]

State Board Actions

State boards of pharmacy hold concurrent jurisdiction over compounding facilities licensed within their borders. The Texas State Board of Pharmacy, the California State Board of Pharmacy, and the Florida Board of Pharmacy have each issued consent orders against compounders selling injectable peptides without adequate sterility documentation. [6] State boards can act faster than the FDA because they do not require federal interagency coordination. A facility may hold a state license in good standing while simultaneously under FDA inspection.

Import Alerts Affecting Raw Peptide API

Several raw peptide API suppliers in China and India have been placed under FDA Import Alert 66-40 (Detention Without Physical Examination of Drugs from Firms Which Have Not Met Drug GMPs). [7] A pharmacy sourcing sermorelin bulk API from a detained supplier is compounding with an unapproved starting material regardless of the final product's apparent purity. Buyers should ask specifically whether the API Certificate of Analysis (CoA) comes from an FDA-registered and inspected supplier.

USP Standards That Govern Sterile Sermorelin Preparations

USP <797>: The Sterile Compounding Standard

USP <797> sets minimum requirements for beyond-use dating, cleanroom classification, personnel garbing and training, environmental monitoring, and sterility testing. The 2023 revision tightened beyond-use dating for Category 1 CSPs (compounded sterile preparations) to 12 hours at controlled room temperature or 24 hours refrigerated when prepared in a non-ISO 5 environment. [8] Sermorelin vials are Category 2 CSPs requiring sterility testing and extended stability data to support the BUDs commonly printed on vials (typically 30 days refrigerated).

USP <85>: Bacterial Endotoxin Testing

Injectable peptides must meet the endotoxin limit of 5 EU/kg/hr for the patient's weight and dose. [9] A 0.3 mg sermorelin injection given to a 70 kg adult must contain no more than 350 EU total, and the pharmacy must demonstrate this through Limulus Amebocyte Lysate (LAL) or recombinant Factor C testing on every lot.

USP <621>: HPLC Purity Testing

Potency and purity testing by high-performance liquid chromatography confirms the peptide's identity and quantifies related impurities, including oxidation products, deamidation fragments, and synthesis by-products. Acceptable purity for injectable sermorelin is ≥98% by HPLC area normalization. [10] Pharmacies should provide a Certificate of Analysis for each lot that includes the HPLC chromatogram, not just a summary percentage.

USP <71>: Sterility Testing

USP <71> requires 14-day incubation in thioglycollate and soybean-casein digest media for each sterility-tested lot. [11] Pharmacies issuing BUDs longer than the default Category 2 limits must perform this test. Ask the pharmacy directly whether each lot number on your vial's label was USP <71> tested or whether the facility uses parametric release based on validated filtration sterilization.

PCAB Accreditation and What It Actually Signals

The Pharmacy Compounding Accreditation Board (PCAB), administered by URAC, provides voluntary accreditation for both sterile and non-sterile compounding pharmacies. PCAB standards align with USP <797> and <795> but add on-site inspection, periodic re-accreditation, and documented quality management systems. [12]

What PCAB Does Not Guarantee

PCAB accreditation confirms that a pharmacy met the standards at the time of the most recent inspection. It does not guarantee that a specific lot of sermorelin was tested correctly, that the API supplier is FDA-registered, or that the labeled potency is accurate. Think of PCAB the way you think of a restaurant health-code grade: necessary but not sufficient.

How to Verify PCAB Status

PCAB maintains a public directory of accredited pharmacies. Verify the pharmacy's name, address, and accreditation expiration date directly on the URAC website before ordering. A pharmacy claiming PCAB status that does not appear in that directory should be treated as unaccredited.

The "Research Use Only" Problem

Injectable sermorelin sold with a "Research Use Only" (RUO) or "Not for Human Use" label is not compounded under 503A or 503B authority. It is an unregulated chemical product. The FDA has stated clearly that labeling a product for research use does not exempt it from the FD&C Act's adulteration and misbranding provisions when the product is intended for human administration. [13]

RUO sermorelin purchased from online peptide vendors typically lacks endotoxin testing, sterility testing, and validated HPLC purity data. A 2021 independent laboratory analysis of 28 commercially available "research peptide" products found that 17 of 28 samples (61%) contained detectable levels of bacterial endotoxins above injectable limits, and 9 of 28 (32%) contained the labeled peptide at less than 85% of the stated concentration. [14]

Practical Buyer Guidance: A Step-by-Step Checklist

The following framework distills FDA enforcement findings, USP standards, and PCAB criteria into a practical verification sequence a patient or prescriber can complete before a sermorelin prescription is filled.

Step 1: Confirm the Facility Type and Registration

Ask whether the pharmacy is a 503A patient-specific compounder or a 503B outsourcing facility registered with the FDA. Search the FDA's 503B outsourcing facility database to confirm registration. [15] A 503A pharmacy requires a valid patient-specific prescription; a 503B facility may dispense without one but must follow CGMP.

Step 2: Verify the API Supplier

Request the API Certificate of Analysis and confirm the supplier's FDA registration number. Cross-check the supplier in FDA's Drug Establishment Registration and Listing database. [16] If the pharmacy cannot or will not provide supplier information, source your prescription elsewhere.

Step 3: Request Lot-Specific Testing Documentation

Ask for the following documents for the specific lot number on your vial:

• HPLC purity report (≥98% area normalization, with chromatogram)
• Bacterial endotoxin test result (LAL or recombinant Factor C, ≤5 EU/kg/hr at prescribed dose)
• USP <71> sterility test result or parametric release documentation
• Beyond-use date justification (stability data or default USP <797> Category 2 limits)

A legitimate 503B facility provides these on request. Refusal is a disqualifying signal. [17]

Step 4: Check Accreditation and Disciplinary History

Verify PCAB accreditation on the URAC directory. Then search the state board of pharmacy's public license lookup for any disciplinary actions, consent orders, or probationary conditions on the facility's license. Most state boards post this information publicly. [18]

Step 5: Confirm Prescriber Involvement

Sermorelin is prescription-only. Any pharmacy dispensing it without a valid prescription from a licensed US prescriber is operating illegally under both federal and state law. The prescriber should have performed a clinical evaluation, ordered baseline IGF-1 and IGFBP-3 levels, and documented a clinical indication before writing the script. [19]

Growth Hormone Secretagogues: The Broader Regulatory Context

Sermorelin is frequently grouped with other growth hormone secretagogues (GHS), including ipamorelin, CJC-1295, tesamorelin, and MK-677. Each has a distinct regulatory status. Tesamorelin (Egrifta) holds FDA approval for HIV-associated lipodystrophy. [20] Ipamorelin and CJC-1295 have no approved formulation and are under active FDA review for the 503A and 503B bulk substance lists. [21]

FDA's 2023 and 2024 Enforcement Signals

In April 2024, FDA issued a guidance document clarifying that it intends to prioritize enforcement against 503B facilities compounding substances not on the approved bulk list or Category 2 list, including several peptides commonly compounded alongside sermorelin. [22] Pharmacies compounding multi-peptide combinations that include an unapproved GHS alongside sermorelin may be producing an illegal combination product regardless of sermorelin's individual permissibility. Patients receiving combination peptide formulations (e.g., sermorelin/ipamorelin blends) should ask specifically about the regulatory basis for each component.

Clinical Evidence Behind Prescribing Decisions

Prescribers choosing sermorelin over recombinant human growth hormone (rhGH) often cite its more physiologic pulsatile stimulation of endogenous GH secretion and its generally lower cost. A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=171) found that sermorelin 0.2 mg subcutaneous daily for 26 weeks increased mean IGF-1 by 39% in adults with GH deficiency compared to a 2% increase in the placebo arm (P<0.001). [23] The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults notes that GHRH analogues represent an alternative secretagogue strategy when pituitary somatotroph reserve is intact, though the guideline emphasizes that diagnosis must precede therapy. [24]

When Enforcement Meets Patient Access

The tension between FDA enforcement activity and patient demand for compounded peptides is not new. The agency's 2016 memo on bulks list development stated that patient access is a consideration in prioritization but cannot override safety concerns from inadequately tested products. [25] Patients who have achieved clinical benefit from compounded sermorelin and face potential supply disruption should work with their prescriber to document clinical response (IGF-1 levels, body composition, validated quality-of-life measures) and explore whether a transition to an FDA-approved GHRH analogue or other therapeutic strategy is appropriate.

Quality Red Flags: What to Walk Away From

Below are specific findings that should cause a buyer or prescriber to reject a compounding pharmacy as a sermorelin source.

• No lot-specific CoA available. A summary potency percentage without the supporting chromatogram is insufficient.
• BUDs exceeding 30 days refrigerated without documented stability data referenced to USP <797> Category 2 requirements.
• API sourced from a supplier not registered in FDA's Drug Establishment Registration and Listing database.
• Injectable product labeled "for research use only" or "not for human use."
• Pharmacy not findable in the FDA 503B outsourcing facility database and not holding a current state pharmacy license in the dispensing state.
• Combination peptide vials containing ipamorelin, CJC-1295, or GHRP-2 alongside sermorelin, without explicit confirmation that each bulk substance has current 503A or 503B authorization.
• Price per vial below $40 for a 15 mg multi-dose vial. Legitimate endotoxin testing, sterility testing, and HPLC analysis cost money. Prices that cannot support those costs signal skipped testing. [26]